Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06300216
Starting soon Observational

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

NCT06300216 · tracked via the Priya Life Science China tracker
Sponsor
Qilu Hospital of Shandong University
Phase
Observational
Started
2024-03-26
Last updated
2024-03-08

Condition(s) studied

Neuroendocrine Tumors

Investigational drug(s) / intervention(s)

Octreotide microspheres

Octreotide microspheres: 20mg/30mg Q4W

Study summary

The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Sign an informed consent form and voluntarily participate in this study; 2. Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study; 3. Age ≥ 18 years old; 4. Treatment with octreotide microspheres. Exclusion Criteria: 1. Confirmed pregnant or lactating women; 2. Participating in any research with intervention measures outside of routine clinical practice; 3. Other situations unsuitable for inclusion in the study determined by the researcher.

Primary outcome measure(s)

  • Treatment Emergent Adverse Events — up to 46 months
    Treatment emergent adverse events were recorded according to Common Terminology Criteria for Adverse Events (version 5.0) of the National Cancer Institute that participants received at least one dose of protocol treatment.

Trial sites (1)

FacilityCityRegionStatus
Qilu hospital of Shandong University Jinan Shandong

More Qilu Hospital of Shandong University trials in China

Efficacy and Safety Analysis of Polylauric Alcohol More Stable Foam Versus Ordinary Foam in the Treatment of Head and Neck Venous Malformations Recruiting
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis Recruiting
Compound Danshen Dripping Pill for Diabetic Microvascular Angina Starting soon
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy Active, not recruiting
Intraoperative Longitude-Latitude-Depth Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for 0.8-2 cm Peripheral Pulmonary Nodules Recruiting

Other trials for the same condition

18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis Recruiting
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs Active, not recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors Recruiting
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study Active, not recruiting
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06300216 on ClinicalTrials.gov ↗ ← All trials in China